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Abstract
Background: We investigated fetal and total DNA levels in maternal plasma in patients bearing
fetuses affected with Down syndrome in comparison to controls carrying fetuses with normal
karyotype.
Methods: DNA levels in maternal plasma were measured using real-time quantitative PCR using
SRY and β -globin genes as markers. Twenty-one pregnant women with a singleton fetus at a
gestational age ranging from 15 to 19 weeks recruited before amniocentesis (carried out for
reasons including material serum screening and advanced material age), and 16 pregnant women
bearing fetuses affected with Down syndrome between 17 to 22 weeks of gestation were involved
in the study.
Results: The specificity of the system reaches 100% (no Y signal was detected in 14 women
pregnant with female fetuses) and the sensitivity 91.7% (SRY amplification in 22 of 24 examined
samples). The median fetal DNA levels in women carrying Down syndrome (n=11) and the
controls (n=13) were 23.3 (range 0–58.5) genome-equivalents/ml and 24.5 (range 0–47.5) genome-
equivalents/ml of maternal plasma, respectively (P = 0.62). The total median DNA levels in
pregnancies with Down syndrome and the controls were 10165 (range 615–65000) genome-
equivalents/ml and 7330 (range 1300–36750) genome-equivalents/ml, respectively (P = 0.32). The
fetal DNA proportion in maternal plasma was 0%-6 % (mean 0.8%) in women carrying Down
syndrome and 0%-2.6 % (mean 0.7 %) in the controls, respectively (P=0.86).
Conclusions: Our study revealed no difference in fetal DNA levels and fetal DNA: maternal DNA
ratio between the patients carrying Down syndrome fetuses and the controls.
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Background
Current experimental non-invasive methods for the pre-
natal diagnosis of fetal genetic characteristics use free ex-
tracellular fetal DNA and fetal cells isolated from maternal
peripheral blood. Free extracellular fetal DNA which can
be detected by polymerase chain reaction (PCR) in the se-
rum or plasma of pregnant women [1] has been previous-
ly successfully used for the prenatal diagnosis of fetal sex
and rhesus D status [2–5]. A novel approach is to monitor
elevations in the fetal DNA levels in pregnancies with
preeclampsia [7,8], aneuploid fetuses [9,10] and preterm
labor [11] using the real-time quantitative PCR technolo-
gy (RQ-PCR) [6]. The study of Zhong et al. also showed
that in preeclampsia, the amounts of both circulatory fetal
and maternal DNA were increased [8].
In this study, we investigated the fetal and total DNA lev-
els in maternal plasma in patients bearing fetuses affected
with Down syndrome in comparison to the controls car-
rying fetuses with normal karyotype. The detection of Y
DNA was used in male fetuses because a generic fetal DNA
marker is not yet available.
Methods
Twenty-one pregnant women with a singleton fetus at a
gestational age ranging from 15 - 19 (Φ  17.) weeks with
an increased risk for an aneuploid fetus who were under-
going an invasive prenatal diagnostic procedure (amnio-
centesis), and 16 pregnant women bearing fetuses affected
with Down syndrome between 17 - 22 (Φ  20.) weeks of
gestation were recruited for this study. Local Ethics Com-
mittee approval and informed consent was obtained for
all patients in the study.
DNA extraction from plasma samples
Five ml of maternal peripheral blood from Down syn-
drome and euploid cases was collected into EDTA con-
taining tubes and processed within a few hours
(maximally 24 h). In details, blood samples were centri-
fuged firstly at 1200 g for 10 min., than plasma samples
were recentrifuged again and the supernatants were col-
lected and stored at -80 ° C until futher processing. Down
syndrome and euploid case samples were matched for
time in storage to take under consideration an eventual
loss of fetal DNA in maternal plasma as a function of time
in freezer storage. The Down syndrome plasma samples
were stored in a freezer for 4,6 (range 1–8) months and
control samples for 5,1 (range 1–8) months before DNA
extraction and RQ-PCR analyses.
DNA was extracted from 400 µl plasma using QIAamp
DNA Blood Mini Kit (Qiagen, Hilden, Germany) accord-
ing to the manufacturer's instructions. To minimize the
risk of contamination, DNA was isolated in laminar air-
flow and aerosol resistant tips were used. DNA was eluted
in 50 µl Buffer AE and 2,5 µl were used as a template for
the RQ-PCR reaction.
Real-time quantitative PCR Analysis
The real time quantitative PCR analysis was performed us-
ing ABI PRISM 7700 Sequence Detection System (Applied
Biosystem, Branchburg, New Jersey, USA). The β -globin
TaqMan system consisted of two primers β -globin-354
(forward), 5'-GTG CAC CTG ACT CCT GAG GAG A-3'; β -
globin-455 (reverse), 5'-CCT TGA TAC CAA CCT GCC
CAG-3' and a dual-labelled fluorescent TaqMan probe β -
globin-402T, 5'(FAM) AAG GTG AAC GTG GAT GAA GTT
GGT GG (TAMRA)-3' [6]. The SRY TaqMan system con-
sisted of SRY-109 (forward) primer, 5'-TGG CGA TTA AGT
CAA ATT CGC-3'; SRY-245 (reverse) primer, 5'-CCC CCT
AGT ACC CTG ACA ATG TAT T-3' and a probe SRY-142T,
5'(FAM) AGC AGT AGA GCA GTC AGG GAG GCA GA
(TAMRA)-3' [6]. Sequence data were obtained from the
GeneBank Sequence database U01317 (β -globin gene)
and L08063 (SRY gene) as was previously described by Lo
et al. [6].
TaqMan amplification reactions were set up in a reaction
volume of 25 µl using the TaqMan Universal PCR Master
Mix (Applied Biosystems, Branchburg, New Jersey, USA).
DNA amplifications were carried out in 8-well reaction
optical tubes/stripes (Applied Biosystem, Branchburg,
New Jersey, USA). The TaqMan PCR conditions were used
as described in TaqMan guidelines using 40 cycles of 95°C
for 15 s and 60°C for 1 min. with 2-min preincubation at
50°C required for optimal AmpErase UNG activity and
10-min preincubation at 95°C required for activation of
AmpliTaq Gold DNA polymerase. Each sample was ana-
lysed in triplicate.
The calibration curve was run in parallel with each analy-
sis. The concentration of the of SRY and β -globin were ex-
pressed in genome-equivalents per millilitre of maternal
plasma.
Statistics
Two-tailed t-test was performed using the SPSS software
package for Windows. A P value of < 0.05 was taken as sta-
tistically significant.
Results
Figure 1 and Figure 2 demonstrate standard curves for SRY
and  β -globin genes plotting the threshold cycle (CT)
against known concentrations of serially diluted mixed
DNA. Target quantity of unknowns was interpolated from
given the CT of any unknown.
In our setting the sensitivity of the RQ-PCR system was
91,7 % as SRY specific PCR amplicons were detected in 22
out of 24 studied samples and the specificity 100 % sinceBMC Pregnancy and Childbirth 2002, 2 http://www.biomedcentral.com/1471-2393/2/4
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no Y chromosome positive signals were detected in 14
women currently pregnant with a female fetus.
The median fetal DNA levels in maternal plasma obtained
from women carrying Down syndrome (n = 11) and the
controls carrying fetuses with normal karyotype (n = 13)
were 23,3 (range 0–58.5) genome-equivalents/ml and
24,5 (range 0–47.5) genome-equivalents/ml. The differ-
ence between the two groups did not reach statistical sig-
nificance (P= 0.62), (Figure 3).
The total median DNA levels in patients bearing fetuses
affected with Down syndrome (n = 16) and the controls
carrying fetuses with normal karyotype (n = 21) were
10165 (range 615 – 65000) genome-equivalents/ml and
7330 (range 1300 – 36750) genome-equivalents/ml of
maternal plasma, respectively (P = 0.32), (Figure 4).
The fetal DNA proportion in maternal plasma was 0 % –
6 % (mean 0,8 %) in women carrying Down syndrome
and 0%–2,6 % (mean 0,7 %) in the controls carrying fe-
tuses with normal karyotype, respectively (P = 0.86).
Discussion
Recently, Lo et al. [9] reported findings of very high con-
centrations of circulating cell-free fetal DNA in maternal
plasma in a proportion of pregnancies involving trisomy
21 fetuses. The median cell-free fetal DNA in women car-
rying trisomy 21 fetuses was found to be 2.96-fold and
1.97-fold higher than that of women carrying euploid fe-
tuses in prospective studies done on samples collected
from two centres. Consequently, Zhong et al. [10] confirm
these results by showing elevated levels of fetal DNA in
pregnancies with trisomy 21 fetuses (mean 185.6 ge-
nome-equivalents/ml) when compared to pregnancies
with normal male fetuses (mean 83.1 genome-equiva-
lents/ml).
Figure 1
Standard curve for SRY gene (in logarithmic scale) plotting
the threshold cycle (CT) against known concentrations of
serially diluted mixed DNA.
Figure 2
Standard curve for β -globin gene (in logarithmic scale) plot-
ting the threshold cycle (CT) against known concentrations
of serially diluted mixed DNA.BMC Pregnancy and Childbirth 2002, 2 http://www.biomedcentral.com/1471-2393/2/4
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Our results showed that fetal DNA levels in maternal plas-
ma were not significantly elevated in pregnancies with
Down syndrome fetuses when comparing to the controls
carrying fetuses with normal karyotype. The median fetal
DNA levels in maternal plasma obtained from women
carrying Down syndrome (n = 11) and the controls carry-
ing fetuses with normal karyotype (n = 13) were 23,3
(range 0–58.5) genome-equivalents/ml and 24,5 (range
0–47.5) genome-equivalents/ml, respectively (P= 0.62).
Plasma samples from women carrying euploid fetuses
were recruited before amniocentesis for indications in-
cluding maternal serum screening and advanced maternal
age and compared with samples from women carrying
Down syndrome fetuses sampling immediately as soon as
possible after karyotype determination. Our data might
confirm recently published results of Ohashi et al. inde-
pendent study who observed no significant differencies in
the levels of fetal DNA between pregnancies with fetuses
of normal karyotype and those with Down and Edwards
syndrome [12]. Several studies reported that plasma DNA
concentration could be affected by different sample
processing protocols [13,14]. The examination of only cir-
culatory fetal DNA, any of initial processing steps con-
cerning a single centrifugation of the blood sample or use
of a discontinuous Percoll density gradient, as well as
plasma fractions subsequently cleared further by high-
speed centrifugation or filtration appear not to make sig-
nificant difference in the concentration of fetal DNA
[13,14]. However in case of maternal plasma, DNA con-
centrations may vary in various studies due to the level of
clearing the plasma of any maternal cellular remnants. By
using sample processing protocol concerning the double
centrifugation of blood samples at 1200 g we found out
comparable fetal DNA levels as those reported by Lo et al.
who separated the plasma using double centrifugation at
3000 g [6]. Differences in total DNA levels and fetal DNA:
maternal DNA ratio in maternal plasma between our re-
sults and those reported by Lo et al. [6] might be caused
by the use of lower-speed and lower-time centrifugation
protocol we used for plasma preparation in our study.
Conclusions
Our study revealed no difference in fetal DNA levels and
fetal DNA: maternal DNA ratio between the patients car-
rying Down syndrome and the controls carrying fetuses
with normal karyotype.
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Figure 3
Levels of fetal DNA in maternal plasma.
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Figure 4
Levels of total DNA in maternal plasma.
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